COVID-19 candidate vaccine mRNA-1273 III clinical trial: the scale will continue to expand.

!---- Clinical Biotech company Moderna is a pioneer in messenger RNA (mRNA) therapeutics and vaccines, and Moderna today announced an additional $472 million investment in BARDA (Biomedical Advanced Research and Development Agency) to support late-stage clinical development, including the expansion of clinical trials of mRNA vaccine candidate s /mRNA-1273 III for COVID-19BARDA has previously received an investment of up to $483 million to support the clinical development of mRNA-1273, however, the initial Phase III clinical trial involved is relatively smallAfter discussions with the U.SFood and Drug Administration (FDA), Moderna decided to conduct a larger Phase III clinical trialUnder the revised terms of the contract, BARDA will expand support for post-clinical development of mRNA-1273, including A Phase III studies of 30,000 participants in the United States"We are grateful to BARDA for its continued support of the COVID-19 candidate vaccine mRNA-1273," said Moderna CEO St?phane BancelEncouraged by the first phase of data, we believe that mRNA-1273 may help address the COVID-19 pandemic and prevent future outbreaks."